Association between the soluble receptor for advanced glycation end products (sRAGE) and NAFLD in participants in the Atherosclerosis Risk in Communities Study.

Atherosclerosis / etiology Biomarkers / blood Cross-Sectional Studies Female Humans Inflammation Liver Cirrhosis / blood Liver Function Tests Logistic Models Male Middle Aged Non-alcoholic Fatty Liver Disease / blood Receptor for Advanced Glycation End Products / blood
Biomarkers Inflammation NAFLD Receptor for advanced glycation end products

Journal

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
ISSN: 1878-3562
Titre abrégé: Dig Liver Dis
Pays: Netherlands
ID NLM: 100958385

Informations de publication

Date de publication:
07 2021
Historique:
received: 18 10 2020
revised: 01 02 2021
accepted: 02 02 2021
pubmed: 1 3 2021
medline: 2 2 2022
entrez: 28 2 2021
Statut: ppublish

Résumé

Inflammation is key in the pathogenesis of Nonalcoholic Fatty Liver Disease (NAFLD) - a common progressive liver disease. The soluble receptor for advanced glycation end products (sRAGE) attenuates inflammatory signaling; low levels of sRAGE are correlated with increased inflammation. We sought to describe associations between sRAGE and NAFLD. We conducted a cross-sectional analysis of 1088 Atherosclerosis Risk in Communities (ARIC) Study participants and used logistic regression to investigate the associations between sRAGE and NAFLD defined by elevated liver enzymes and fibrosis score. In this community-based sample (n = 1,088, mean age 56 years, 61% female, 78% Caucasian), persons in the lowest vs. highest quartile of sRAGE had significantly higher odds of elevated ALT (OR 2.82, 95% CI 1.18-6.76) but not elevated AST (OR 1.16, 95% CI 0.45-2.99); persons in the lowest vs. highest quartile had significantly lower odds of elevated FIB-4 index (OR 0.56, 95% CI 0.37-0.84). We found an inverse cross-sectional association between sRAGE and liver inflammation; this is consistent with prior studies linking low sRAGE to inflammatory states. However, we observed a direct association between sRAGE and fibrosis. Our findings suggest that sRAGE is dynamic in NAFLD and patterns may vary with different stages of disease.

Sections du résumé

BACKGROUND
Inflammation is key in the pathogenesis of Nonalcoholic Fatty Liver Disease (NAFLD) - a common progressive liver disease. The soluble receptor for advanced glycation end products (sRAGE) attenuates inflammatory signaling; low levels of sRAGE are correlated with increased inflammation.
AIM
We sought to describe associations between sRAGE and NAFLD.
METHODS
We conducted a cross-sectional analysis of 1088 Atherosclerosis Risk in Communities (ARIC) Study participants and used logistic regression to investigate the associations between sRAGE and NAFLD defined by elevated liver enzymes and fibrosis score.
RESULTS
In this community-based sample (n = 1,088, mean age 56 years, 61% female, 78% Caucasian), persons in the lowest vs. highest quartile of sRAGE had significantly higher odds of elevated ALT (OR 2.82, 95% CI 1.18-6.76) but not elevated AST (OR 1.16, 95% CI 0.45-2.99); persons in the lowest vs. highest quartile had significantly lower odds of elevated FIB-4 index (OR 0.56, 95% CI 0.37-0.84).
CONCLUSIONS
We found an inverse cross-sectional association between sRAGE and liver inflammation; this is consistent with prior studies linking low sRAGE to inflammatory states. However, we observed a direct association between sRAGE and fibrosis. Our findings suggest that sRAGE is dynamic in NAFLD and patterns may vary with different stages of disease.

Identifiants

DOI: 10.1016/j.dld.2021.02.005 PMID: 33640303 PMC: PMC8238805
pubmed: 33640303
pii: S1590-8658(21)00057-8
doi: 10.1016/j.dld.2021.02.005
pmc: PMC8238805
mid: NIHMS1677968
pii:
doi:

Substances chimiques

AGER protein, human 0
Biomarkers 0
Receptor for Advanced Glycation End Products 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

873-878

Subventions

Organisme : NHLBI NIH HHS
ID : K24 HL152440
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007180
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700002C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700004I
Pays : United States
Organisme : NIAAA NIH HHS
ID : K23 AA028297
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700004C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700003I
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK072488
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700001I
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700005C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700001C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700003C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700002I
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700005I
Pays : United States

Informations de copyright

Copyright © 2021 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None.

Références

Clin Pharmacol Ther. 2015 Aug;98(2):135-44
pubmed: 25974754
Am J Epidemiol. 1989 Apr;129(4):687-702
pubmed: 2646917
Am Heart J. 2015 Nov;170(5):961-7
pubmed: 26542505
Transplantation. 2007 Sep 15;84(5):659-63
pubmed: 17876282
Hepatology. 2019 Jun;69(6):2672-2682
pubmed: 30179269
Annu Rev Med. 2018 Jan 29;69:349-364
pubmed: 29106804
Mol Cell Endocrinol. 2019 Jan 5;479:20-26
pubmed: 30170183
Eur J Med Res. 2015 Feb 11;20:15
pubmed: 25888859
Best Pract Res Clin Gastroenterol. 2002 Oct;16(5):663-78
pubmed: 12406438
J Hepatol. 2013 Oct;59(4):859-71
pubmed: 23751754
J Clin Med. 2018 Aug 15;7(8):
pubmed: 30111756
J Hepatol. 2014 Apr;60(4):832-8
pubmed: 24316518
Hepatology. 2013 Oct;58(4):1339-48
pubmed: 23703665
Int J Endocrinol. 2019 Sep 18;2019:2151302
pubmed: 31641351
Hepatology. 2003 Jul;38(1):50-6
pubmed: 12829986
Diabetes. 2014 Jun;63(6):1948-65
pubmed: 24520121
J Hepatol. 2015 Apr;62(4):841-7
pubmed: 25433159
Cardiovasc Diabetol. 2008 Oct 07;7:29
pubmed: 18840258
J Hepatol. 2019 Mar;70(3):531-544
pubmed: 30414863
Neurology. 2014 Apr 29;82(17):1536-42
pubmed: 24696507
Arch Pharm Res. 2015 Jul;38(7):1317-24
pubmed: 25559468
Sci Rep. 2016 Mar 03;6:22450
pubmed: 26936329
Hepatology. 2001 Nov;34(5):943-52
pubmed: 11679965
Gastroenterology. 2011 Jan;140(1):124-31
pubmed: 20858492
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20
pubmed: 28930295
Metabolism. 2017 Jul;72:57-65
pubmed: 28641784
Clin Gastroenterol Hepatol. 2009 Oct;7(10):1104-12
pubmed: 19523535
Liver Int. 2010 Apr;30(4):546-53
pubmed: 20074094
Metabolism. 2018 Jun;83:120-127
pubmed: 29409822
Diabetes. 2017 Jun;66(6):1683-1695
pubmed: 28385802
Gastroenterology. 2015 Mar;148(3):547-55
pubmed: 25461851
Kidney Int. 2010 Feb;77(3):225-31
pubmed: 19924100
Nat Clin Pract Endocrinol Metab. 2008 May;4(5):285-93
pubmed: 18332897
Diabetes. 2013 Jun;62(6):2116-21
pubmed: 23396398
Clin Chem. 2017 May;63(5):980-989
pubmed: 28280052
World J Gastroenterol. 2016 Sep 21;22(35):8026-40
pubmed: 27672297
N Engl J Med. 2017 Nov 23;377(21):2063-2072
pubmed: 29166236
Clin Biochem. 2014 Jan;47(1-2):132-4
pubmed: 24246851
Circulation. 2002 Nov 26;106(22):2827-35
pubmed: 12451010
Int J Biochem Cell Biol. 2014 Dec;57:54-62
pubmed: 25310905
J Biol Chem. 2008 Dec 19;283(51):35507-16
pubmed: 18952609
Eur J Clin Nutr. 2019 Aug;73(8):1133-1140
pubmed: 30341433
Hepatology. 2006 Jun;43(6):1317-25
pubmed: 16729309
Front Biosci (Elite Ed). 2010 Jun 01;2:1184-95
pubmed: 20515790

Auteurs

Marci Laudenslager (M)

Department of Medicine, Division of General Internal Medicine, The Johns Hopkins School of Medicine, Baltimore, MD, United States. Electronic address: mlauden1@jhmi.edu.

Mariana Lazo (M)

Department of Community Health and Prevention and the Urban Health Collaborative, Drexel University Dornsife School of Public Health, Philadelphia, PA, United States. Electronic address: ml3629@drexel.edu.

Dan Wang (D)

Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States. Electronic address: dwang77@jhu.edu.

Elizabeth Selvin (E)

Department of Medicine, Division of General Internal Medicine, The Johns Hopkins School of Medicine, Baltimore, MD, United States; Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States. Electronic address: eselvin@jhu.edu.

Po-Hung Chen (PH)

Department of Medicine, Division of Gastroenterology and Hepatology, The Johns Hopkins School of Medicine, Baltimore, MD, United States. Electronic address: pchen37@jhmi.edu.

James S Pankow (JS)

Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, MN, United States. Electronic address: panko001@umn.edu.

Jeanne M Clark (JM)

Department of Medicine, Division of General Internal Medicine, The Johns Hopkins School of Medicine, Baltimore, MD, United States; Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States. Electronic address: jmclark@jhmi.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies cardiovasculaires › Maladies vasculaires › Artériopathies oblitérantes › Artériosclérose › Athérosclérose › Association between the soluble receptor for...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Association between the soluble receptor for...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études transversales › Association between the soluble receptor for...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Association between the soluble receptor for...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Inflammation › Association between the soluble receptor for...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Fibrose › Cirrhose du foie › Association between the soluble receptor for...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic digestif › Tests de la fonction hépatique › Association between the soluble receptor for...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de régression › Modèles logistiques › Association between the soluble receptor for...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Association between the soluble receptor for...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Stéatose hépatique › Stéatose hépatique non alcoolique › Association between the soluble receptor for...
questionsmedicales.fr › Facteurs biologiques › Médiateurs de l'inflammation › Récepteur spécifique des produits finaux de glycosylation avancée › Association between the soluble receptor for...